These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 18948736)

  • 1. The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs.
    Di Agostino S; Cortese G; Monti O; Dell'Orso S; Sacchi A; Eisenstein M; Citro G; Strano S; Blandino G
    Cell Cycle; 2008 Nov; 7(21):3440-7. PubMed ID: 18948736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of p73 gene overexpression on apoptosis and chemosensitivity of human lung adenocarcinoma cell line A549.
    He Y; Fan SZ; Jiang YG
    Ai Zheng; 2006 Aug; 25(8):925-32. PubMed ID: 16965670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway.
    Kravchenko JE; Ilyinskaya GV; Komarov PG; Agapova LS; Kochetkov DV; Strom E; Frolova EI; Kovriga I; Gudkov AV; Feinstein E; Chumakov PM
    Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6302-7. PubMed ID: 18424558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
    Zhang S; Zhou L; Hong B; van den Heuvel AP; Prabhu VV; Warfel NA; Kline CL; Dicker DT; Kopelovich L; El-Deiry WS
    Cancer Res; 2015 Sep; 75(18):3842-52. PubMed ID: 26294215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hydroxyurea on the promoter occupancy profiles of tumor suppressor p53 and p73.
    Huang V; Lu X; Jiang Y; Wang JY
    BMC Biol; 2009 Jun; 7():35. PubMed ID: 19558638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type p53 and p73 negatively regulate expression of proliferation related genes.
    Scian MJ; Carchman EH; Mohanraj L; Stagliano KE; Anderson MA; Deb D; Crane BM; Kiyono T; Windle B; Deb SP; Deb S
    Oncogene; 2008 Apr; 27(18):2583-93. PubMed ID: 17982488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells.
    Million K; Horvilleur E; Goldschneider D; Agina M; Raguénez G; Tournier F; Bénard J; Douc-Rasy S
    Int J Oncol; 2006 Jul; 29(1):147-54. PubMed ID: 16773194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53.
    Hong B; Prabhu VV; Zhang S; van den Heuvel AP; Dicker DT; Kopelovich L; El-Deiry WS
    Cancer Res; 2014 Feb; 74(4):1153-65. PubMed ID: 24247721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
    Zhang L; Nie L; Maki CG
    Mol Cancer; 2006 Dec; 5():68. PubMed ID: 17150106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line.
    Vikhanskaya F; D'Incalci M; Broggini M
    Nucleic Acids Res; 2000 Jan; 28(2):513-9. PubMed ID: 10606650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity.
    Ozaki T; Sugimoto H; Nakamura M; Hiraoka K; Yoda H; Sang M; Fujiwara K; Nagase H
    FEBS J; 2015 Jan; 282(1):114-28. PubMed ID: 25331851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity.
    Blanch A; Robinson F; Watson IR; Cheng LS; Irwin MS
    PLoS One; 2013; 8(6):e66436. PubMed ID: 23799104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells.
    Righetti SC; Perego P; Carenini N; Zunino F
    Cancer Lett; 2008 May; 263(1):140-4. PubMed ID: 18261847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-of-function mutants.
    Lanza M; Marinari B; Papoutsaki M; Giustizieri ML; D'Alessandra Y; Chimenti S; Guerrini L; Costanzo A
    Cell Cycle; 2006 Sep; 5(17):1996-2004. PubMed ID: 16931914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ΔNp73β on cisplatin treatment in colon cancer cells.
    Lööf J; Pfeifer D; Ding Z; Sun XF; Zhang H
    Mol Carcinog; 2012 Aug; 51(8):628-35. PubMed ID: 21837762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity.
    Tomasini R; Seux M; Nowak J; Bontemps C; Carrier A; Dagorn JC; Pébusque MJ; Iovanna JL; Dusetti NJ
    Oncogene; 2005 Dec; 24(55):8093-104. PubMed ID: 16044147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p73 beta-expressing recombinant adenovirus: a potential anticancer agent.
    Das S; Nama S; Antony S; Somasundaram K
    Cancer Gene Ther; 2005 Apr; 12(4):417-26. PubMed ID: 15678153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation.
    Lapi E; Iovino A; Fontemaggi G; Soliera AR; Iacovelli S; Sacchi A; Rechavi G; Givol D; Blandino G; Strano S
    Oncogene; 2006 Jun; 25(26):3628-37. PubMed ID: 16449968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.